PX’Therapeutics Licenses ribOvax Biotechnologies SA (Ribovax)'s SEBVI Technology for the Development and Manufacturing of Fully Human Monoclonal Antibodies

Published: Jul 27, 2011

GRENOBLE, France--(BUSINESS WIRE)--PX’Therapeutics SA (PX’T) and ribOvax Biotechnologies SA (Ribovax) have announced that they have entered into a licensing agreement to provide PX’T with access to Ribovax’s patented SEBVI Technology for the discovery and development of antibodies of entirely human origin.

Back to news